Thirty-five people who say they suffered from “severe withdrawal reactions” after taking the anti-depressant Paxil filed a class-action complaint against the drug’s maker Friday in California Superior Court.
The complaint against pharmaceutical giant GlaxoSmithKline, which produces Paxil, alleges that the drug “is more addictive” and “has a greater tendency to induce physical and physiological dependency” than other anti-depressants.
Paxil, which was introduced to the U.S. market in December of 1992, is one of several anti-depressants classified as a selective seratonin reuptake inhibitor, or an S.S.R.I. drug. Other well known S.S.R.I. drugs are Prozac, which is manufactured by Eli Lilly; and Zoloft, made by Pfizer.
A section of the complaint charges that “GlaxoSmithKline has known for years the distinct characteristics of Paxil which make it prone to cause withdrawal reactions when discontinued.”
A U.S.-based spokeswoman for GSK, which has its headquarters in London, said the company does not have a statement at this time.